New York 2025-2026 Regular Session

New York Senate Bill S01225

Introduced
1/8/25  
Refer
1/8/25  
Engrossed
4/28/25  
Refer
4/28/25  
Refer
1/7/26  
Engrossed
3/5/26  

Caption

Requires periodic reviews of pending applications for material change in the coverage status of certain matters relative to new health technology assessment or medical evidence.

Summary

Bill S01225 amends the social services law to mandate periodic reviews of pending applications for material changes in the coverage status of health technologies and medical evidence. The bill requires the commissioner, in consultation with a committee, to review applications within three months of receipt and to notify applicants of any incompleteness within thirty days. It also stipulates that the department must publish the receipt of applications and the date of reviews on its website, ensuring transparency in the review process. Additionally, the bill mandates that the committee consider any matters regarding changes in coverage status and conduct systematic evidence-based assessments of health technologies or services proposed for review.

Impact

This bill will enhance the efficiency and transparency of the review process for health technology assessments in New York. By requiring timely reviews and public notifications, it aims to streamline the decision-making process regarding health coverage changes. The bill also emphasizes the importance of evidence-based assessments, which may lead to more informed decisions regarding the approval of new health technologies and services. This could potentially impact healthcare providers, patients, and manufacturers by altering how new technologies are evaluated and integrated into health coverage.

Sentiment

The sentiment surrounding Bill S01225 appears to be overwhelmingly positive, as evidenced by the unanimous votes in both the Senate Health Committee and the Senate Floor for its final passage. The discussions leading up to the votes suggest a strong consensus on the need for improved processes in health technology assessments, reflecting a collaborative approach among lawmakers to enhance healthcare delivery in New York.

Contention

While the overall sentiment is positive, there may be underlying concerns regarding the adequacy of the evidence required for committee deliberations and the potential for delays in the approval process for new technologies. Some stakeholders, particularly those representing healthcare providers and manufacturers, may have differing views on the sufficiency of evidence and the implications of the review timelines mandated by the bill.

Companion Bills

NY A11025

Same As Requires periodic reviews of pending applications for material change in the coverage status of certain matters relative to new health technology assessment or medical evidence

Previously Filed As

NY A11025

Requires periodic reviews of pending applications for material change in the coverage status of certain matters relative to new health technology assessment or medical evidence.

NY HB87

Insurance; require health benefit policy coverage for medically necessary orthotic and prosthetic devices and their materials and components

NY SB2694

Health insurance; require coverage for biomarker testing for certain purposes when supported by medical and scientific evidence.

NY HB05521

An Act Concerning Sterile Cultivars, Application Requirements For The Use Of Certain Materials As Fill And The Revision Of Certain Housing-related Statutes.

NY S722

Establishes "New Jersey Menopause Coverage Act"; requires health insurance coverage of medically necessary perimenopause and menopause treatments.

NY HF668

Medical assistance coverage of drugs covered by a primary third-party payer required, and coverage of in-network services by medical assistance regardless of network or referral status for a primary third-party payer required.

NY S3760

Requires certain law enforcement officers be periodically vetted for evidence of personal bias.

NY S07297

Relates to utilization review program standards; requires use of evidence-based and peer reviewed clinical review criteria; relates to prescription drug formulary changes and pre-authorization for certain health care services.

NY A03789

Relates to utilization review program standards; requires use of evidence-based and peer reviewed clinical review criteria; relates to prescription drug formulary changes and pre-authorization for certain health care services.

NY S09651

Relates to utilization review program standards; requires use of evidence-based and peer reviewed clinical review criteria; relates to prescription drug formulary changes and pre-authorization for certain health care services.

Similar Bills

US HR198

Providing for the expenses of certain committees of the House of Representatives in the One Hundred Nineteenth Congress.

MN HC1

A house concurrent resolution relating to the regent nomination joint committee.

IL HR0020

HOUSE RULES-AMEND

CA AB1350

Employment Development Department: policies and practices.

NM HJM2

Combine Standing & Interim Committees

MN HC2

A House concurrent resolution relating to the adjournment of the House of Representatives and Senate until 2026.

CA SB829

California Institute for Scientific Research: CalRx Initiative: vaccines.

AR HB1573

To Reorganize The Standing Committees And The Subject Matter Interim Committees Of The House Of Representatives.